New research being presented at the European Congress on Obesity (ECO 2025) has found that patients of an online obesity ...

Neurologist Dr. Leah Croll talks about the new research suggesting they might help in treating people with alcohol use ...

David Kessler has lost more than 60 pounds on weight-loss drugs and believes they can change the trajectory of chronic ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at ...

Scientists have been studying other possible health benefits of GLP-1s. Popular obesity and diabetes drugs called GLP-1 ... use disorder," Dr. Maurice O'Farrell, lead author of the study and ...

People booze a lot less when taking GLP-1 drugs like Ozempic, a new study out of Ireland ... statistics show. Monkey Business – stock.adobe.com Harmful alcohol use accounts for about 2.6 million ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, ...

Study presented at DDW ... trial design to support drug development. The study titled, "A Genetic Risk Score Associated with Nausea Resulting from GLP-1 Agonist Treatment: A Post-Hoc Analysis ...

Ozempic and similar drugs aren’t just for weight loss, more and more research is finding. New data is the latest to show that GLP-1 medications ... for alcohol use disorder, the study ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after revenue more than doubled, and it raised full-year guidance. Revenue hit $ ...